Research Guide
Peptide Dosing Guide for Researchers
Research-focused guide to peptide dosing fundamentals. Covers unit conversions, concentration calculations, subcutaneous injection volumes, bioavailability by route, titration principles, and dose-response design with PubMed citations.
Dosing is where peptide research moves from theory to practice. A researcher can understand every molecular mechanism, know the target receptor, and have a clear hypothesis — but without accurate dosing, the experiment produces nothing reliable. The dose determines whether a compound reaches its target at a biologically active concentration or falls below the threshold of detectable effect.
Peptide dosing introduces specific challenges that small-molecule chemistry does not. Peptides are measured in micrograms (mcg), not milligrams. Injection volumes are measured in fractions of a milliliter. Concentration depends on the mass of peptide in a vial, the volume of solvent added during reconstitution, and the fraction of that volume drawn into a syringe. A miscalculation at any point in this chain produces a dose that is either too low to register biologically or too high to be scientifically meaningful.
This guide covers the three pillars of accurate peptide dosing in research: the units and arithmetic of concentration calculations, the range of doses used in published preclinical and clinical research for different peptide classes, and the principles of dose-response design — how researchers structure protocols to find the minimum effective dose and characterize the relationship between dose and biological response.
Nothing in this guide constitutes dosing advice for human subjects. All dose ranges referenced are drawn from published preclinical studies, clinical trials, or pharmacokinetic research. Researchers should consult institutional review boards and qualified pharmacologists when designing protocols involving peptide administration.
Overview
Peptide dosing operates on a different scale than most pharmaceutical research. Where a typical small-molecule drug might be dosed in hundreds of milligrams, many research peptides are active at microgram levels — a thousand-fold difference. This scale difference has practical consequences for every step of the dosing process.
The fundamental chain of peptide dosing begins with the lyophilized vial. A vial contains a known mass of peptide — typically 2 mg, 5 mg, 10 mg, or 15 mg — in dry powder form. During reconstitution, a measured volume of bacteriostatic water is added, creating a solution of known concentration. The researcher then draws a calculated volume from this solution to deliver a precise dose.
Three variables determine the delivered dose: the peptide mass in the vial (set by the manufacturer), the reconstitution volume (chosen by the researcher), and the injection volume (calculated from the desired dose and the resulting concentration). Changing any one of these variables changes the delivered dose, which is why the arithmetic must be explicit and verified.
Bioavailability — the fraction of administered peptide that reaches systemic circulation — varies dramatically by route. Subcutaneous injection, the most common route for research peptides, typically yields bioavailability of 50–90% for peptides under 10 kDa PMID: 3385825 . Intramuscular injection is broadly similar. Oral bioavailability is generally below 5% for unmodified peptides due to gastrointestinal protease degradation, though certain sequences (notably BPC-157 
BPC-157 pentadecapeptide Gastrointestinal protection & systemic tissue repair ) show oral activity in animal models that challenges this generalization PMID: 25529739 . Intranasal delivery bypasses first-pass metabolism and is the primary route for neuropeptides like Semax 
Semax synthetic heptapeptide derived from adrenocorticotropic hormone ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance and Selank Selank synthetic heptapeptide derived from tuftsin Tuftsin-derived anxiolytic peptide studied for immune modulation and stress response .
Understanding bioavailability is essential for comparing doses across routes. A 250 mcg subcutaneous dose and a 250 mcg intranasal dose of the same peptide do not deliver the same amount to systemic circulation — the subcutaneous dose may deliver 125–225 mcg after absorption losses, while the intranasal dose may deliver a different fraction depending on nasal mucosal absorption characteristics.
Concentration, not just dose, affects research outcomes. Higher concentrations (e.g., 5 mg/mL vs. 1 mg/mL) reduce injection volume but increase the risk of peptide aggregation in solution and may cause local irritation at the injection site. Lower concentrations require larger volumes, which exceed comfortable subcutaneous injection limits (typically 1–1.5 mL per site) PMID: 10821397 . Finding the optimal concentration for each peptide is part of protocol design, not an afterthought.
How They Work Together
Dosing accuracy, bioavailability knowledge, and dose-response design are interdependent. A researcher who understands concentration calculations but ignores bioavailability may deliver an effective dose at one route and a subtherapeutic dose at another using the same injection volume. A researcher who designs a dose-response study but uses inaccurate concentration math may place subjects in the wrong dose groups entirely.
The three components work as a system. Concentration arithmetic ensures the correct mass of peptide reaches the syringe. Bioavailability knowledge translates the administered dose into an estimate of what actually reaches systemic circulation. Dose-response design structures the experiment so that the relationship between dose and effect can be characterized with statistical rigor.
In practice, this means every peptide protocol should explicitly state: the peptide mass in the vial, the reconstitution volume and resulting concentration, the injection volume for each dose level, the route of administration with estimated bioavailability, and the dose expressed in both mcg and mcg/kg (for weight-normalized studies).
For researchers working with multiple peptides simultaneously — for example, BPC-157 BPC-157 pentadecapeptide Gastrointestinal protection & systemic tissue repair and TB-500 
TB-500 synthetic tetrapeptide fragment (of Thymosin Beta-4) Systemic tissue repair & angiogenesis in a tissue repair study — each peptide requires independent concentration calculations and potentially different reconstitution volumes. The convenience of reconstituting all vials with the same volume must be weighed against the optimal concentration for each peptide's stability and aggregation characteristics.
The research literature provides the starting point for all dosing decisions, but individual experimental conditions — species, strain, age, sex, health status, and the specific endpoint being measured — require researchers to calibrate doses within their own experimental system. Published dose ranges are guidelines, not prescriptions.
Frequently Asked Questions
Frequently Asked Questions
-
Micrograms (mcg or μg) and milligrams (mg) are metric mass units: 1 mg = 1,000 mcg. Most research peptides are dosed in the mcg range (100–1,000 mcg typical) rather than the mg range. IU (International Units) is a biological activity measurement used for insulin and some vitamins — it does not apply to most research peptides. The confusion arises because insulin syringes (marked in "units" where 100 units = 1 mL) are commonly used to inject peptides, but the syringe markings measure volume (0.01 mL per unit), not peptide mass. A researcher must calculate the appropriate volume based on their specific peptide concentration.
-
Use this formula: Injection volume (mL) = Desired dose (mcg) / Concentration (mcg/mL). For example, if your concentration is 2,500 mcg/mL and your desired dose is 250 mcg: 250 / 2,500 = 0.1 mL. On a U-100 insulin syringe (where 100 units = 1 mL), this equals 10 units. Always verify your concentration calculation first: Concentration (mcg/mL) = Vial mass (mg) × 1,000 / Reconstitution volume (mL).
-
Peptides are biologically active at much lower masses than small-molecule drugs. This reflects their mechanism: peptides bind to specific cell-surface receptors with high affinity, triggering signaling cascades at very low occupancy rates. A typical receptor-binding peptide may produce a maximal biological response when fewer than 10% of available receptors are occupied — a phenomenon known as receptor reserve. This means only a small number of peptide molecules (micrograms) are needed to activate a large downstream response. Small-molecule drugs, by contrast, often require milligram quantities because they work through enzyme inhibition or other mechanisms that demand higher molar concentrations.
-
Yes. Subcutaneous bioavailability for most peptides ranges from 50–90% [PMID: 3385825]. This means that of a 500 mcg subcutaneous dose, approximately 250–450 mcg reaches systemic circulation. The remaining fraction is degraded by proteases in the subcutaneous tissue, binds to local extracellular matrix proteins, or is cleared by local lymphatic drainage before reaching the bloodstream. This is normal and expected — published dose ranges for subcutaneous peptides already account for this loss. The key is consistency: using the same injection technique, site, and depth across experimental groups ensures that bioavailability is consistent even if it is not 100%.
-
Clinical guidance limits subcutaneous injection volume to 1–1.5 mL per injection site [PMID: 10821397]. Volumes exceeding this threshold cause local pain, swelling, and unpredictable absorption kinetics due to tissue distension. If a dose requires a larger volume at standard concentration, the options are: (1) increase the peptide concentration by using less reconstitution solvent, (2) split the dose across two injection sites, or (3) switch to intramuscular injection, which accommodates larger volumes (up to 3 mL in large muscles).
-
Simple mg/kg scaling does not work for interspecies dose conversion because metabolic rate, body surface area, and clearance rates scale allometrically — not linearly — with body mass. The FDA recommends body surface area (BSA) normalization using the formula: Human equivalent dose (mg/kg) = Animal dose (mg/kg) × (Animal Km / Human Km), where Km = body weight / BSA. For common research animals: mouse Km = 3, rat Km = 6, human Km = 37. So a 10 mcg/kg dose in a rat translates to approximately 10 × (6/37) ≈ 1.6 mcg/kg in a human. This conversion is approximate and intended for initial estimation in clinical trial design, not for direct application.
-
Dose requirements reflect several factors: receptor affinity (how tightly the peptide binds its target), signal amplification (how much downstream response each binding event produces), distribution volume (how widely the peptide disperses in the body), metabolic clearance rate (how quickly the peptide is degraded), and the density of target receptors in the tissue of interest. A peptide with high receptor affinity, strong signal amplification, and slow clearance (like Semax, active at microgram doses intranasally) requires far less mass than a peptide with lower affinity and rapid clearance.
-
A dose-response curve plots the magnitude of a biological effect (y-axis) against the dose of a compound (x-axis). It typically has a sigmoidal shape: no effect at very low doses, a steep increase over a narrow dose range, and a plateau at high doses. The curve matters because it reveals the minimum effective dose (where the effect first becomes detectable), the EC50 (the dose producing 50% of maximum effect — a standard measure of potency), and the maximum effective dose (beyond which increasing dose produces no additional effect). Without characterizing this curve, a researcher cannot distinguish a genuinely negative result (the compound does not work) from a dosing error (the compound was tested at a subthreshold or supratherapeutic dose).
-
Mixing peptides in a single injection is technically possible but generally avoided in controlled research for several reasons. Chemical interactions between peptides in solution (cross-linking, competitive binding to excipients, pH incompatibility) may alter the stability or bioactivity of one or both compounds. If one peptide degrades faster than the other, the ratio changes over time, making dose calculations unreliable. Additionally, if an adverse reaction occurs, it becomes impossible to determine which peptide caused it. The standard research practice is to administer each peptide as a separate injection, at separate sites if given simultaneously, with independent concentration calculations and labeling.
-
PubMed (https://pubmed.ncbi.nlm.nih.gov/) is the primary source for published dose ranges. Search for the peptide name plus terms like 'dose-response,' 'pharmacokinetics,' 'preclinical safety,' or 'toxicology.' For preclinical dose ranges, animal model studies provide the most specific data — search for the peptide name plus 'rat' or 'mouse' plus the tissue or system of interest. Clinical dose data, where it exists, is found in Phase I/II trial publications. Key databases include ClinicalTrials.gov (for registered trial protocols with dose information) and the FDA's approved labeling documents for approved peptide drugs (semaglutide, tirzepatide, liraglutide). The compound pages on CompoundGuide also reference published dose ranges for individual peptides.
Summary
Peptide dosing is fundamentally an exercise in precision. The microgram scale at which peptides are active means that small errors in unit conversion, concentration calculation, or injection volume produce proportionally large errors in delivered dose. Mastering the arithmetic — mass to concentration to volume — is a prerequisite for any peptide research protocol.
Bioavailability adds a second layer of complexity. The same mass of peptide delivered by different routes produces different systemic exposures. Subcutaneous injection, the workhorse of peptide research, delivers roughly half to most of the administered dose to circulation. Oral delivery, for most peptides, delivers very little. Understanding these differences is essential for interpreting published dose ranges and designing experiments that produce interpretable results.
Dose-response design provides the framework for moving from published literature to experimental practice. Starting with the minimum effective dose, escalating incrementally, and characterizing the full dose-response curve allows researchers to identify optimal dosing parameters for their specific experimental context.
As with all aspects of peptide research, the primary literature — accessible through PubMed — remains the most reliable source of dosing information. Published pharmacokinetic studies, toxicology reports, and dose-ranging experiments provide the empirical foundation on which protocol design rests. For reconstitution specifics, see the Peptide Reconstitution Guide. For storage and stability, see Peptide Storage & Handling.